Clinical trials: Pseudomonas Infections
Pseudomonas Aeruginosa Respiratory Tract Infection/Colonization, Cystic Fibrosis
Study of Aztreonam for Inhalation in Children With Cystic Fibrosis and New Infection of the Airways by Pseudomonas Aeruginosa Bacteria
The primary objective of this study is to evaluate the safety and efficacy of a 14-day course versus a 28-day course of aztreonam for inhalation solution (AZLI) in pediatric participants with new onset Pseudomonas aeruginosa…
- Trial name
- ALPINE 2 (NCT03219164)
- Testing
- AZLI
- Where
- 53 sites in United States, Austria and 10 more
- Volunteers
- 149 people
- Sponsor
- Gilead Sciences
Surgical Wound Infection, Cross Infection
Reducing Intraoperative ESKAPE Transmission Through Use of a Personal Hand Hygiene System
The investigators hypothesize that the use of a personal hand hygiene system (SafeHavenTM) by anesthesia providers in the adult operating room, combined with a novel infectious pathogen tracking system (OR PathTrac) will decrease…
- Trial name
- ESKAPE (NCT04900298)
- Testing
- SafeHaven Automated Hand Hygiene Device
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Oregon Health and Science University
Tracheostomy Infection
The Use of Inhaled Aztreonam in Children With a Tracheostomy Tube and Pseudomonas
This is a prospective, case-control clinical trial using inhaled Aztreonam (AZLI) in pediatric patients with a tracheostomy tube colonized with Pseudomonas aeruginosa.
- Trial name
- A-PACT (NCT03158116)
- Testing
- Inhaled Aztreonam
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- UCSF Benioff Children's Hospital Oakland
Bronchiectasis, Cystic Fibrosis
Ceftolozane/Tazobactam Continuous Infusion for Infective Exacerbations of Cystic Fibrosis and Bronchiectasis
The goal of this clinical trial is to assess the feasibility of ceftolozane/tazobactam (C/T) administered on an outpatient parenteral antibiotic therapy programme to patients with a current infective exacerbation of…
- Conditions
- Bronchiectasis, Cystic Fibrosis, Pseudomonas Aeruginosa, Burkholderia Cepacia Infection
- Trial name
- CERTAIN (NCT06035055)
- Testing
- Ceftolozane/tazobactam
- Volunteers
- 30 people
- Sponsor
- Sunshine Coast Hospital and Health Service
Cystic Fibrosis, Pseudomonas Aeruginosa
Cross Transmissions of Pseudomonas Aeruginosa Between Children From a Same Cystic Fibrosis Center.
Cystic fibrosis is the most common hereditary autosomal recessive disease in the Caucasian population. The diseases is caused by a mutation of the gene coding for the CFTR protein (Cystic fibrosis transmembrane conductance…
- Conditions
- Cystic Fibrosis, Pseudomonas Aeruginosa, Cross Infection
- Trial name
- PAPED (NCT03910920)
- Where
- Belgium
- Volunteers
- 15 people
- Sponsor
- Queen Fabiola Children's University Hospital
Neutrophil Extracellular Traps Formation
Neutrophil Extracellular Traps (NETs) Mediated Killing of Carbapenem-resistant Pseudomonas Aeruginosa.
Aim of the work: To determine the killing ability of neutrophils to ATCC 27853, carbapenem-resistant P. aeruginosa. To compare between the ability of ATCC 27853, carbapenem-resistant P. aeruginosa to induce NETs formation.
- Trial name
- NCT06441708
- Testing
- No intervention
- Volunteers
- 50 people
- Sponsor
- Assiut University
Cystic Fibrosis
Bacteriophage Effects on Pseudomonas Aeruginosa
Pulmonary phage therapy to treat bacterial infections of the respiratory tract have been investigated in animals. The aim of the present study is to evaluate the efficacy of bacteriophages in infecting Pseudomonas aeruginosa (PA)…
- Trial name
- MUCOPHAGES (NCT01818206)
- Testing
- Collection of induced sputum in order to evaluate the efficacy of a cocktail of 10 bacteriophages.
- Where
- France
- Volunteers
- 59 people
- Sponsor
- University Hospital, Montpellier
Pseudomonas Aeruginosa
Pathobiomes in Gut of Critically Ill Patients
Despite powerful antibiotics, 50% of the intestinal tracts of critically ill surgical patients are colonized by Pseudomonas aeruginosa, whose mere presence in this site increases mortality fourfold by mechanisms that remain…
- Trial name
- NCT06822465
- Testing
- P. aeruginosa using in vitro and in vivo assays
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University of Chicago
Infection Due to Resistant Organism
FMT for MDRO Colonization After Infection in Renal Transplant Recipients
Transplant patients are at increased risk of colonization and infection with Multidrug Resistant Organisms (MDROs) due to medications that modify their immune systems, increased healthcare and antibiotic exposure, and surgical…
- Trial name
- PREMIX (NCT02922816)
- Testing
- Fecal Microbiota Transplant (FMT), Bowel preparation, Stool or perirectal swab sampling
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Emory University
Cystic Fibrosis, Pseudomonas Aeruginosa
Continuous Versus Short Infusions of Ceftazidime in Cystic Fibrosis
The aim of this trial was to compare the safety and efficacy of courses of tobramycin and ceftazidime, administered intravenously as either thrice daily short infusions or 24 h continuous infusion, in cystic fibrosis patients…
- Conditions
- Cystic Fibrosis, Pseudomonas Aeruginosa, Pulmonary Exacerbation
- Trial name
- NCT00333385
- Testing
- ceftazidime
- Where
- 15 sites in France
- Volunteers
- 120 people
- Sponsor
- Association Nationale pour les Traitements A Domicile, les Innovations et la Recherche
Cystic Fibrosis
Pharmacokinetic Study of Bramitob® Administered for Inhalation by PARI eFlow® vs PARI LC® PLUS Nebulizer
The purpose of this study is to assess pharmacokinetic and safety comparability of Bramitob® when administered for inhalation by using PARI eFlow® rapid electronic nebulizer vs PARI LC® PLUS nebulizer in Cystic Fibrosis Patients…
- Trial name
- NCT01116089
- Testing
- Bramitob® administered by PARI LC® PLUS nebulizer, Bramitob® administered by PARI eFlow® rapid electronic nebulizer
- Where
- 5 sites in Czechia, Moldova and 1 more
- Volunteers
- 25 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Bronchiectasis
Identification of Microbiome and Metabolome of Bronchiectasis in Chinese Population.
This study aims to investigate the characteristics of gut microbiome and metabolome in non-CF bronchiectasis patients, hoping to explore the underlying mechanisms as well as the influence of gut microbiota composition on…
- Trial name
- NCT04490447
- Where
- China
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Bronchiectasis, Lower Respiratory Infection
Safety, Efficacy and PK/PD of POL7080 in Patients With Exacerbation of Non-cystic Fibrosis Bronchiectasis.
To test whether POL7080 is effective in patients with exacerbation of non-cystic fibrosis bronchiectasis caused by Pseudomonas aeruginosa infection.
- Trial name
- NCT02096315
- Testing
- POL7080
- Where
- 4 sites in Spain, United Kingdom
- Volunteers
- 20 people
- Sponsor
- Polyphor Ltd.
Individual Patient Expanded Access for AB-PA01, an Investigational Anti-Pseudomonas Aeruginosa Bacteriophage Therapeutic
The purpose of the expanded access program is to allow physicians to provide treatment with investigational drug, AB-PA01, for patients with serious or immediately life-threatening Pseudomonas aeruginosa infections, for which no…
- Trial name
- NCT03395743
- Testing
- AB-PA01
- Sponsor
- Armata Pharmaceuticals, Inc.
Pseudomonas Infection
Safety, Tolerability and PK 3-Period Crossover Study Comparing 2 Single Doses of ZTI-01 and Monurol® in Healthy Subjects
The objective is to determine the safety, tolerability and pharmacokinetics (PK) of 2 single doses of ZTI-01 (1g and 8g infused over 1-hr) and a single dose of the Reference Label Drug, Monurol® (oral sachet, 3g).
- Trial name
- NCT02178254
- Testing
- Fosfomycin tromethamine, Fosfomycin disodium
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Cystic Fibrosis
A Study Comparing the Efficacy and Tolerability of Tobrineb®/Actitob®/Bramitob® Versus TOBI®
The objectives of the study are to demonstrate that Tobrineb®/Actitob®/Bramitob® is non-inferior to TOBI® in the primary efficacy variable, forced expiratory volume in one second (FEV1) percent of predicted normal, and to compare…
- Trial name
- CT03 Core (NCT00885365)
- Testing
- tobramycin / Bramitob, tobramycin / TOBI
- Where
- 44 sites in Czechia, France and 6 more
- Volunteers
- 324 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Pseudomonas Infections, Pseudomonas Aeruginosa
Antimicrobial Therapy for Difficult-to-treat Pseudomonas Aeruginosa
The primary objective of the ADDICT study is to assess and compare the clinical efficacy of available options for antimicrobial therapy (new beta-lactam/beta-lactamase inhibitor combination, cefiderocol or older agents such as…
- Conditions
- Pseudomonas Infections, Pseudomonas Aeruginosa, Prognosis, Drug Resistance, Multiple, Bacterial
- Trial name
- ADDICT (NCT06738771)
- Where
- 48 sites in France, Reunion
- Volunteers
- 600 people
- Sponsor
- Centre Hospitalier Régional d'Orléans
Pulmonary Infections, Pseudomonas Aeruginosa in Cystic Fibrosis
Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis
This study assessed the long term safety data for the use of tobramycin inhalation powder in patients suffering from cystic fibrosis who have a chronic pulmonary infection with Pseudomonas aeruginosa.
- Trial name
- NCT01519661
- Testing
- TBM100
- Where
- 49 sites in United States, Argentina and 8 more
- Volunteers
- 157 people
- Sponsor
- Novartis Pharmaceuticals
Cystic Fibrosis
RATNO, Reducing Antibiotic Tolerance Using Nitric Oxide in CF - a Phase 2 Pilot Study
The lungs of most patients with cystic fibrosis (CF) become chronically infected with bacteria called Pseudomonas aeruginosa during childhood.
- Trial name
- RATNO (NCT02295566)
- Testing
- Nitric Oxide, Control
- Where
- United Kingdom
- Volunteers
- 12 people
- Sponsor
- University Hospital Southampton NHS Foundation Trust